Weijie Li Selected Research

Weijie Li Research Topics

Disease

15	Neoplasms (Cancer) 03/2022 - 01/2012
12	Rheumatoid Arthritis 09/2022 - 03/2002
11	Inflammation (Inflammations) 12/2022 - 01/2012
6	Insulin Resistance 06/2013 - 02/2005
5	Lung Neoplasms (Lung Cancer) 03/2022 - 11/2013
4	Infections 01/2021 - 01/2014
4	Atherosclerosis 12/2012 - 02/2010
4	Type 2 Diabetes Mellitus (MODY) 12/2011 - 06/2004
3	Crohn Disease (Crohn's Disease) 01/2021 - 01/2020
3	Hyperplasia 08/2019 - 01/2007
3	Hypoxia (Hypoxemia) 10/2017 - 01/2011
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 07/2016 - 03/2015
2	Myocardial Infarction 01/2022 - 07/2014
2	Carcinogenesis 01/2022 - 01/2021
2	Asthma (Bronchial Asthma) 01/2022 - 02/2002
2	Arthritis (Polyarthritis) 01/2022 - 01/2021
2	Breast Neoplasms (Breast Cancer) 01/2022 - 02/2017
2	Infarction (Infarctions) 07/2021 - 02/2003
2	Fibrosis (Cirrhosis) 03/2020 - 07/2014
2	Hepatocellular Carcinoma (Hepatoma) 10/2019 - 09/2012
2	Hepatitis 01/2019 - 01/2014
2	Hepatitis B 02/2018 - 01/2014
2	Liver Neoplasms (Liver Cancer) 01/2018 - 09/2012
2	Adenocarcinoma of Lung 02/2016 - 11/2013
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/2015 - 03/2013
2	Autoimmune Diseases (Autoimmune Disease) 03/2013 - 08/2003
2	Hyperglycemia 12/2011 - 02/2005
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 12/2009 - 03/2008
2	Psoriasis (Pustulosis Palmaris et Plantaris) 03/2008 - 02/2007
1	Death (Near-Death Experience) 01/2022
1	Hemorrhage 01/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 01/2022

Drug/Important Bio-Agent (IBA)

11	Proteins (Proteins, Gene)FDA Link 03/2020 - 03/2002
9	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2014
6	Pharmaceutical PreparationsIBA 01/2021 - 11/2013
5	TabletsIBA 01/2021 - 01/2018
5	Glucose (Dextrose)FDA LinkGeneric 10/2015 - 02/2005
5	Insulin (Novolin)FDA Link 01/2013 - 06/2004
4	LigandsIBA 01/2022 - 01/2014
4	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2012
4	GlycosidesIBA 01/2021 - 01/2018
4	Phosphotransferases (Kinase)IBA 03/2015 - 01/2007
4	AdiponectinIBA 01/2013 - 06/2004
3	Drug CombinationsIBA 09/2022 - 01/2020
3	guizhi decoctionIBA 01/2022 - 02/2020
3	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2015
3	ChemokinesIBA 01/2022 - 01/2020
3	Adenosine Triphosphate (ATP)IBA 01/2021 - 12/2011
3	Biological ProductsIBA 01/2021 - 12/2012
3	ErbB Receptors (EGF Receptor)IBA 07/2016 - 02/2007
3	Messenger RNA (mRNA)IBA 01/2015 - 02/2007
3	Pioglitazone (Actos)FDA Link 06/2013 - 06/2004
2	LipidsIBA 12/2022 - 01/2016
2	mangiferinIBA 09/2022 - 01/2022
2	InflammasomesIBA 01/2022 - 01/2021
2	ORALIT (ORS)IBA 01/2022 - 01/2022
2	Competitive Endogenous RNAIBA 01/2022 - 10/2020
2	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2021 - 02/2020
2	src-Family KinasesIBA 01/2021 - 12/2009
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021 - 02/2005
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 02/2020 - 02/2002
2	peoniflorinIBA 01/2020 - 01/2020
2	Liposomes (Liposome)IBA 12/2019 - 01/2014
2	Small Interfering RNA (siRNA)IBA 12/2019 - 01/2014
2	Folic Acid (Vitamin M)FDA LinkGeneric 12/2019 - 01/2014
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 02/2019 - 02/2003
2	Hepatitis B e AntigensIBA 02/2018 - 01/2014
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2018 - 01/2014
2	Tyrosine Kinase InhibitorsIBA 07/2016 - 02/2016
2	Cisplatin (Platino)FDA LinkGeneric 01/2016 - 11/2013
2	Toll-Like Receptor 4IBA 10/2015 - 01/2011
2	CoumarinsIBA 10/2015 - 03/2013
2	ThiazolidinedionesIBA 06/2013 - 06/2004
2	Plasminogen Activator Inhibitor 1IBA 12/2012 - 02/2010
2	CathepsinsIBA 08/2003 - 03/2002
2	Cathepsin KIBA 07/2002 - 03/2002
1	Glycyrrhizic Acid (Glycyrrhizin)IBA 09/2022
1	Long Noncoding RNAIBA 03/2022
1	Antineoplastic Agents (Antineoplastics)IBA 03/2022
1	Actins (F Actin)IBA 03/2022
1	ZeaxanthinsIBA 01/2022
1	CryptoxanthinsIBA 01/2022
1	Interleukin-18 (Interleukin 18)IBA 01/2022
1	cinnamic acidIBA 01/2022
1	Carotenoids (Carotene)IBA 01/2022
1	LycopeneIBA 01/2022
1	LuteinIBA 01/2022
1	ChloridesIBA 07/2021
1	Chimeric Antigen ReceptorsIBA 01/2021
1	N- (2- (4- bromocinnamylamino)ethyl)- 5- isoquinolinesulfonamide (h89)IBA 01/2021

Therapy/Procedure

16	Therapeutics 09/2022 - 06/2004
7	Drug Therapy (Chemotherapy) 01/2022 - 11/2013
3	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/2022 - 03/2013
2	Precision Medicine 01/2021 - 01/2018
2	Stents 02/2019 - 03/2002
1	Photothermal Therapy 03/2022
1	Radiotherapy 01/2022
1	Adjuvant Chemotherapy 01/2022
1	Modified Radical Mastectomy (Mastectomy, Modified) 01/2022